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Alteration of Ventricular Fibrillation by Flecainide,
Verapamil, and Sotalol
An Experimental Study
Francisco J. Chorro, MD; Joaquı´n Ca´noves, MD; Juan Guerrero, PhD; Luis Mainar, MD;
Juan Sanchis, MD; Luis Such, MD; Vicente Lo´pez-Merino, MD
Background—The purpose of this study was to determine whether the myocardial electrophysiological properties are
useful for predicting changes in the ventricular fibrillatory pattern.
Methods and Results—Thirty-two Langendorff-perfused rabbit hearts were used to record ventricular fibrillatory activity
with an epicardial multiple electrode. Under control conditions and after flecainide, verapamil, or d,l-sotalol, the
dominant frequency (FrD), type of activation maps, conduction velocity, functional refractory period, and wavelength
(WL) of excitation were determined during ventricular fibrillation (VF). Flecainide (1.960.3 versus 2.460.6 cm,
P,0.05) and sotalol (2.160.3 versus 2.560.5 cm, P,0.05) prolonged WL and diminished FrD during VF, whereas
verapamil (2.060.2 versus 1.760.2 cm, P,0.001) shortened WL and increased FrD. Simple linear regression revealed
an inverse relation between FrD and the functional refractory period (r50.66, P,0.0001), a direct relation with respect
to conduction velocity (r50.33, P,0.01), and an inverse relation with respect to WL estimated during VF (r50.49,
P,0.0001). By stepwise multiple regression, the functional refractory periods were the only predictors of FrD.
Flecainide and sotalol increased the circuit size of the reentrant activations, whereas verapamil decreased it. The 3 drugs
significantly reduced the percentages of more complex activation maps during VF.
Conclusions—The activation frequency is inversely related to WL during VF, although a closer relation is observed with
the functional refractory period. Despite the diverging effects of verapamil versus flecainide and sotalol on the activation
frequency, WL, and size of the reentrant circuits, all 3 drugs reduce activation pattern complexity during VF.
(Circulation. 2000;101:1606-1615.)
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Modification of cardiac electrophysiological propertiesand analysis of its repercussions on the activation
patterns have provided useful information for furthering our
knowledge of atrial fibrillatory processes.1–5 Interpretation of
antiarrhythmic drug action on ventricular fibrillation (VF)
entails the added difficulty of myocardial metabolic impair-
ment secondary to the interruption of coronary perfusion.6–10
The use of experimental models in which myocardial perfu-
sion is maintained during VF8,10–12 facilitates analysis of the
characteristics of the arrhythmia and its relation to the
electrophysiological properties of the ventricular myocardi-
um, as in studies of atrial fibrillation.2–5,13–16 The present
study investigates the pharmacological modifications of the
VF activation pattern induced by 3 antiarrhythmic drugs
(flecainide, verapamil, and d,l-sotalol) in the isolated rabbit
heart using both time- and frequency-domain techniques and
analysis of the epicardial activation maps. The purpose of the
study is to analyze the variations in activation frequency and
the complexity of the fibrillatory pattern produced by these
drugs and to determine whether the modifications in myocar-
dial electrophysiological properties are useful for predicting
changes in the ventricular fibrillatory processes.
Methods
Experimental Preparation
The procedures followed in this study conformed to institutional and
NIH guidelines for the care and use of laboratory animals (NIH
publication 85-23, revised 1985).
Thirty-two California rabbits (mean weight, 3.960.6 kg) were
used. After anesthesia with ketamine (25 mg/kg IM) and hepariniza-
tion, the hearts were removed and immersed in cold (4°C) Tyrode’s
solution. After isolation, the aorta was connected to a Langendorff
system for perfusing the Tyrode’s solution at a pressure of
50 mm Hg and a temperature of 3760.5°C. The millimolar compo-
sition of the perfusion fluid was NaCl 130, NaHCO3 24.2, KCl 4.7,
CaCl2 2.2, NaH2PO4 1.2, MgCl2 0.6, and glucose 12. Oxygenation
was carried out with a mixture of 95% O2 and 5% CO2.
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A plaque with 121 unipolar stainless steel electrodes (diameter,
0.125 mm; interelectrode distance, 1 mm) was positioned at the
epicardial surface of the lateral wall of the left ventricle. The
indifferent electrode was a 436-mm silver plaque located over
the cannulated aorta. Ventricular pacing was performed with
bipolar electrodes (diameter, 0.125 mm; interelectrode distance,
1 mm) located in the upper or central zone of the multiple
electrode. Pacing (2-ms rectangular pulses, intensity twice the
diastolic threshold) was carried out with a GRASS S88 stimulator
with a stimulus isolation unit (SIU5). Recordings were obtained
with a cardiac electrical activity mapping system (MAPTECH).
The electrograms were amplified with a gain of 100 to 300,
broadband (1 to 400 Hz) filtered, and multiplexed. The sampling
rate in each channel was 1 kHz.
Experimental Protocol
Thirty minutes after the electrodes were positioned, the extrastimulus
test with 2 extrastimuli was applied. The basic cycle (S0S0) was fixed
at 250 ms. The first extrastimulus (S1) was fixed at the minimum S0S1
interval that captured the ventricles when this interval was reduced in
steps of 10 ms from 200 ms. The second extrastimulus (S2) was
delivered at increasing S1S2 intervals in steps of 2 ms until an interval
10 ms longer than the minimum S1S2 that captured the ventricles. VF
was induced by pacing at increasing frequencies from 4 to 20 Hz,
and coronary perfusion was maintained during the arrhythmia.
Recordings were analyzed 30 seconds after the onset of VF. The
heart was defibrillated 5 minutes after VF induction by a DC shock
(5 J). After 15 minutes, the protocol was repeated when the
antiarrhythmic drug was added to the Tyrode’s solution: flecainide
(1 mmol, n510), verapamil (0.2 to 0.8 mmol, n512), or d,l-sotalol
(20 mmol, n510). The concentrations of flecainide,17–19 d,l-
sotalol,20,21 and verapamil22,23 were selected from the range in which
their characteristic electrophysiological effects are observed. In the
case of verapamil, dose adjustment was also made according to the
effect elicited on the AV Wenckebach cycle length, choosing
the concentration that produced a prolongation of this parameter of
$50%.
Data Analysis
Constant Pacing at the Basic Train (250 ms)
The following parameters were determined: (1) Effective ventricular
refractory period (EVRP) for S2, or the maximum S1S2 interval that
failed to induce ventricular activation. (2) Functional ventricular
refractory period (FVRP), or the minimum V1V2 interval.
(3) Ventricular conduction velocity, determined at the minimum
V1V2 interval in both the longitudinal (VELG) and transverse
(VELTR) direction of propagation. It was estimated by dividing the
distance between 2 electrodes positioned 5 interelectrode spaces
apart in the direction of maximum velocity as indicated by the
isochrones or perpendicular to the former by the time interval
between them. (4) Wavelength of the ventricular activation process
(WL), or the product of the FVRP and the longitudinal conduction
velocity.
Ventricular Fibrillation
Spectral analysis: Welch’s method24 was used to obtain the power
spectrum of the signals recorded with 5 electrodes: 4 located in the
midzone of each of the sides of the multiple electrode, and the fifth
positioned in its central zone. The analysis was performed involving
a data block of 2048 points (sampling rate, 1 kHz) (Figure 1). This
2-second window of the VF recordings began at the 30th second after
the onset of the arrhythmia. The dominant frequency (FrD) and the
energy contained in the segment of the periodogram corresponding
to FrD61 Hz was obtained for each block. Data processing was
performed with Matlab software on a Hewlett-Packard 712/80
platform.
Time-domain Analysis: Activation times in each electrode were
determined by identifying the moment of maximum negative slope
of the electrograms. The minimal threshold for dV/dt to be judged as
a local deflection was a percentage (20%) of the maximal negative
slope in each channel. The fibrillation interval (VV) histograms and
the median (MN) of the consecutive VV intervals were determined
during the same 2-second time windows.
Analysis of the Epicardial Activation Maps During VF: The maps
were constructed every 100 ms in the 2-second time windows of the
VF recordings. Isochrones were drawn semiautomatically at 5-ms
intervals, and each map was classified into 3 categories based on its
complexity13: type I, single broad wave fronts propagating uniformly
without significant conduction delay; type II, 2 wave fronts or 1
wave front with areas of conduction block or slow conduction; and
type III, $3 wave fronts associated with areas of slow conduction
and conduction block (Figure 2). Likewise, for each map, the
presence of activation patterns corresponding to complete reentry
was analyzed (Figure 3). In these maps, the electrodes activated on
the internal portion of the reentrant wave front were identified by
Figure 1. Power spectrum (right) and recordings obtained dur-
ing 2-second time window beginning at 30th second of VF
onset with 1 epicardial electrode (left) under control conditions
and after drug administration. FrD decreases with flecainide and
d,l-sotalol and increases with verapamil.
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Figure 2. Types of activation maps according to complexity. Left, Type I; center, type II; and right, type III. Top, Activation maps. Bot-
tom, Selected electrograms along trajectory of wave fronts.
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Figure 2. Continued
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Figure 3. Consecutive activation maps (1 and 2) obtained during VF showing complete reentry activation pattern. Locations of elec-
trodes A to G are indicated, selected along trajectory of reentrant waveform; corresponding recordings are shown at bottom.
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display of successive 10-ms time windows. These electrodes delim-
ited the central core, whose maximum diameter (ie, length of the
central core) was measured with the grid electrode matrix as
reference. The area encompassed by the central core plus 2 elec-
trodes recording the reentrant activation and the number of consec-
utive rotations were also determined.
Conduction Velocity During VF (VELVF): In the maps in which the
activation front entered the area encompassed by the electrode, without
evidence of breakthrough, velocity was calculated by dividing the distance
between 2 electrodes positioned 5 interelectrode spaces apart in a direction
perpendicular to the isochrones by the difference between their activation
times (average of 5 determinations).
Functional Refractory Period During VF (FRPVF): The minimum
intervals between 2 successive activations by 2 different wave fronts
were determined (Figure 4). FRPVF was regarded as the average of
the 5 smallest values.
Figure 4. Consecutive ventricular activation maps obtained during VF, showing how zone activated by wave front entering from
upper left of map 1 to conduction block on reaching middle zone at right (electrodes A to D) is activated immediately after by
another, different wave front entering from lower right in map 2 (electrodes G to A). Time between 2 successive activations of
electrode D is 44 ms. FRPVF was taken as average of 5 smallest intervals obtained on analysis of all maps in which this activa-
tion pattern was repeated.
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WL During VF: WLVF, or the product of FRPVF and VELVF,
was analyzed.
Statistical Calculations
Data are presented as mean6SD. Comparisons between 2 sets of
data were made with Student’s t test for paired and unpaired data.
The differences between qualitative variables were analyzed by x2
test. Differences were considered significant for P,0.05. The linear
regressions between pairs of variables were made by the least-
squares method. Stepwise regression was used for multiple linear
regression analysis.
Results
Effects on Electrophysiological Parameters During
Constant Pacing (250 ms)
Both flecainide and d,l-sotalol significantly prolonged FVRP
and EVRP, and flecainide reduced the conduction velocity
(VELG and VELTR) (Table 1). Verapamil produced a slight
shortening of the FVRP, without significant variations in
EVRP or conduction velocity. None of the 3 drugs modified
WL. Reproducibility of the determinations after a repeated
induction of VF without adding any drug was tested, and no
significant differences were found (Figure 5).
Drug Effects on the Fibrillatory Pattern
Electrophysiological Parameters During VF
Flecainide and d,l-sotalol significantly prolonged FRPVF and
WLVF and reduced VELVF (Table 1). Verapamil reduced
FRPVF and WLVF, although without changes in VELVF.
Spectral Analysis
Flecainide and d,l-sotalol produced a decrease in the FrD
determined by the 5 selected electrodes, without significant
variations in the energy contained in the interval FrD61 Hz,
whereas verapamil increased both parameters (Table 2).
Analysis in the Time Domain
Flecainide and d,l-sotalol produced an increase in the median
of the VV intervals (MN) determined in each of the 5 selected
electrodes or in the combined electrodes (Table 3). Verapamil
produced a decrease in this parameter.
Analysis of the Activation Maps
In all 3 study groups, the most frequent activation maps under
control conditions corresponded to type II (type I: flecainide
control, 15%; verapamil control, 19%; sotalol control, 11%;
type II: flecainide control, 46%; verapamil control, 49%;
sotalol control, 52%; type III: flecainide control, 39%; verap-
amil control, 32%; sotalol control, 37%), and patterns exhib-
iting complete reentry were recorded in 18 maps (9%) of the
flecainide group, in 14 maps (7%) of the verapamil group,
and in 12 maps (6%) of the d,l-sotalol group.
Figure 5. Reproducibility of determinations after repeated
induction of VF without any drug (n57). 1st and 2nd indicate
first and second determinations; 30s, 60s, 120s, and 298s,
2-second time windows of VF recordings analyzed at 30, 60,
120, and 298 seconds from onset of VF.
TABLE 1. Electrophysiological Parameters (Mean6SD) Obtained in Each
Group of Experiments
Flecainide Verapamil Sotalol
Control Drug Control Drug Control Drug
EVRP, ms 114614 131618* 120613 111615 129616 143620*
FVRP, ms 123612 143616† 130611 118615* 139616 154618*
VELG, cm/s 59.2616.0 47.6614.5‡ 56.3615.4 60.9612.5 56.266.7 51.668
VELTR, cm/s 23.369.9 16.464.8* 19.463.2 20.662.7 23.263.3 22.464.6
WL, cm 7.362.3 6.862.1 7.362.1 7.161.5 7.861.1 7.961.8
FRPVF, ms 4164 7067‡ 4765 3962‡ 4765 66611‡
VELVF, cm/s 47.266.6 34.667.4‡ 43.164.3 43.364.7 45.465.1 39.065.8*
WLVF, cm 1.960.3 2.460.6* 2.060.2 1.760.2‡ 2.160.3 2.560.5*
Significance of the control vs drug differences: *P,0.05, †P,0.01, ‡P,0.001.
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There were significant variations in the percentage of
activation maps after administration of the 3 drugs
(P,0.001), with a decrease in type III maps and an increase
in maps of types I and II (type I: flecainide, 36%; verapamil,
24%; sotalol, 28%; type II: flecainide, 51%; verapamil, 58%;
sotalol, 58%; type III: flecainide, 13%; verapamil, 18%;
sotalol, 14%).
The number of activation maps with complete reentry
patterns was 12 (6%) under the influence of flecainide, versus
14 (7%) and 12 (6%) with verapamil and d,l-sotalol, respec-
tively. During flecainide perfusion, the number of consecu-
tive rotations of reentrant activation did not vary (control,
1.460.6; flecainide, 1.360.5), whereas the length of the
central core increased (control, 561; flecainide, 761 mm;
P,0.001), as did the area encompassed by the central zone
and the 2 electrodes recording the reentrant activation (con-
trol, 4566; flecainide, 6466 mm2; P,0.001).
Verapamil produced an increase in the number of consec-
utive rotations in the maps exhibiting reentry patterns (con-
trol, 1.360.4; verapamil, 2.161.1; P,0.02), with a signifi-
cant decrease in the length of the central core (control, 561;
verapamil, 461 mm; P,0.02) and the calculated area (con-
trol, 4964; verapamil, 3765 mm2; P,0.001).
d,l-Sotalol produced no significant variation in the
number of consecutive rotations (control, 1.260.3; sotalol,
1.060.1), although increments were observed both in the
length of the central core (control, 561; sotalol, 761 mm;
P,0.001) and in area (control, 4366; sotalol, 5767 mm2;
P,0.001).
Relation Between FrD and
Electrophysiological Parameters
When the data corresponding to the control condition and
after drug administration were considered jointly, the regres-
sion lines obtained on relating FrD (in Hz) to the MN (in ms)
or its inverse (IMN, in Hz) were as follows: FrD50.19
MN128.6; r50.88; n564; P,0.0001; SEE51.9 Hz; SE of
the constant51; SE of the coefficient50.01. FrD51.0
IMN20.02; r50.92; n564; P,0.0001; SEE51.6 Hz; SE of
the constant50.82; SE of the coefficient50.06.
Simple regression analysis yielded significant results with
the following parameters: EVRP (r50.51, P,0.0001), FVRP
(r50.59, P,0.0001), FRPVF (r50.66, P,0.0001), VELG
(r50.31, P,0.01), VELVF (r50.33, P,0.01), and WLVF
(r50.49, P,0.0001). By stepwise multiple regression, the
independent variables entered in the function were in first
place FRPVF, and in second place FVRP (r50.71,
P,0.0001).
TABLE 2. Parameters (Mean6SD) Obtained by Spectral Analysis of the Fibrillatory Signal
Flecainide Verapamil Sotalol
Control Drug Control Drug Control Drug
FrD, Hz
E1 14.761.5 9.461.9‡ 14.461.4 20.462.1‡ 12.661.4 10.761.3‡
E2 14.862.1 9.362.8‡ 14.462.7 20.461.8‡ 12.961.1 10.361.7‡
E3 15.861.9 9.662.0‡ 14.762.2 20.461.6‡ 13.261.4 11.561.8†
E4 15.962.8 9.861.9‡ 14.562.4 20.361.9‡ 12.561.2 10.961.9†
E5 16.262.2 10.361.9‡ 14.962.2 19.962.8‡ 12.361.4 11.261.3*
EG, Nu
E1 0.2560.03 0.2560.04 0.2560.05 0.3060.04* 0.2960.04 0.2660.04
E2 0.2660.03 0.2460.04 0.2460.03 0.3060.05† 0.2460.05 0.2560.05
E3 0.2560.04 0.2660.05 0.2560.05 0.3260.04† 0.2660.05 0.2760.02
E4 0.2460.04 0.2560.04 0.2660.05 0.3160.05* 0.2760.06 0.2660.04
E5 0.2560.03 0.2460.06 0.2260.05 0.2960.06* 0.2560.04 0.2660.03
E1 to E5 indicate electrodes; Nu, normalized units.
Significance of the control vs drug differences: *P,0.05, †P,0.01, ‡P,0.001.
TABLE 3. Median of VV Intervals (Mean6SD) During Ventricular Fibrillation
Median, ms
Flecainide Verapamil Sotalol
Control Drug Control Drug Control Drug
E1 69611 95610* 7568 5265* 8369 100611*
E2 68610 97614* 7368 5266* 77612 99613*
E3 6366 95612* 7566 5165* 8068 94613*
E4 6369 9569* 7367 5065* 83612 99621†
E5 6269 94611* 7366 5165* 7969 96614*
All 6468 95610* 7467 5165* 8068 96613*
E1 to E5 and All indicate electrodes.
Significance of the control vs drug differences: *P,0.001, †P,0.01.
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Discussion
Effects of Flecainide, d,l-Sotalol, and Verapamil on
the Frequency of Activation During VF
Spectral analysis and VV histograms demonstrate the slowing
effect of flecainide and d,l-sotalol and the accelerating action
of verapamil. The slowing of VF has also been reported with
both sotalol and tedisamil.12,25 Flecainide has been found to
slow arrhythmia in experimental models of atrial fibrillation,2
although the information available in the context of VF is
limited. In an earlier study,9 we observed a decrease in the
FrD of VF. This slowing effect has also been reported for
other type I drugs, such as lidocaine,6,7 propafenone,11 and
procainamide.26 A series of studies have found nifedipine,
diltiazem, and verapamil to retard the slowing process of the
arrhythmia in VF models in which coronary perfusion was
not maintained.6–9 In addition, FrD has been seen to increase
in the first moments of the arrhythmia under the action of
nifedipine,8 and a shortening of the VF VV intervals after
local and intravenous verapamil perfusion has been report-
ed.27 The results of our study support the existence of a direct
effect of verapamil on the VF pattern that is not related to
protection against ischemia or to sympathetic reflexes trig-
gered by the drug.
Modification of the WL During Arrhythmia
WL exhibits an inverse relation to inducibility of arrhyth-
mia.1,28,29 Opposite actions on refractoriness and conduction
velocity lead to variable results in WL.1,2,4,26 Flecainide reduces
conduction velocity and increases refractoriness. These effects
have been explained in terms of prolonged binding kinetics to
the sodium channels and postrepolarization refractoriness.2,30,31
In the present study, the determinations made with 250-ms
cycles show a balanced and counterposed action on both
parameters; during VF, however, the predominance of the action
on refractoriness led to a significant increase in WL. This fact
has been described in atrial fibrillation,2 although it has also been
reported that WL is not prolonged by flecainide or hydroquini-
dine.4 The effects of d,l-sotalol centered predominantly on
refractoriness. This action is attributable primarily to cardiac
potassium channel block.3,20,21,30,32 The effects may be expected
to decrease during VF because of a reverse use-dependence.
However, the increase in VF cycle length produced by class III
antiarrhythmic drugs12,25 is explained in terms of concomitant
increments in refractoriness. In the present study, we observed a
slowing of the arrhythmia associated with an increase in WL
attributable to the effect on refractoriness. With verapamil, a
slight decrease in the functional refractory period and a short-
ening of the WL during the arrhythmia were observed, associ-
ated with VF acceleration under the influence of the drug.
During atrial fibrillation, the increase in WL implies a
decrease in both the number of wave fronts and the activation
frequency.2,3 In the present study, significant and inverse corre-
lations were obtained between FrD and WL; however, more
important correlations were obtained when the refractory periods
were used. Other factors, such as the presence of an excitable
gap, could determine the activation frequency during the ar-
rhythmia.4 The widening of the excitable gap would imply a
time increment between 2 successive activations.
Variations in Reentrant Circuit Size and
Arrhythmia Complexity
Faster atrial reentrant rhythms based on smaller intramyocar-
dial circuits and the opposite effects have been described.28
Procainamide produces an increase in the core size of the
reentrant wave fronts and a slowing of VF.26 Cromakalim (an
ATP-sensitive potassium channel opener) reduces the central
core of functional reentries and the reentry cycle length.33 In
the present study, we observed concordant variations in
reentrant circuit size, activation cycle length, and WLVF.
Conversely, flecainide and d,l-sotalol produced a reduction in
the complexity of the activation maps. This observation
would be related to the decrease in ventricular activation
frequency during VF and to the increase in WLVF and
reentrant circuit size induced by these drugs. However,
verapamil was found to produce the opposite effects, and
these phenomena were not associated with a greater complex-
ity of the activation maps. There was also an increase in the
energy contained in the segment of the periodogram corre-
sponding to FrD61 Hz that indicates more regular activation
patterns. The increases in intracellular calcium levels after the
development of VF34 and in the minimal level of calcium
after decrease of pacing intervals35 suggest that drugs that
modify intracellular calcium interfere with the fibrillatory
processes.
Various factors could be related to the reduction in VF
complexity produced by verapamil. On one hand, we see the
reduction in the slope of the electrical restitution and in the
action potential duration alternans produced by the drug
(Riccio et al36). The decrease in the oscillation of action
potential duration would reduce the wave breaks during VF,
thus increasing the spatiotemporal organization of the ar-
rhythmia.36 On the other hand, during VF, it has been shown
that both fast and slow channels participate in myocardial
activation.7,27 The L-type calcium channel blocking effect of
verapamil could modify the oscillations of the conduction
velocity, the reduction of which has been related to increased
organization in cardiac activation.37 Further research is
needed to clarify this subject.
Limitations of the Study
VF occurs in a 3-dimensional setting. In this context, the
influence of breakthrough phenomena has been diminished in
the determination of VELVF by use of only those maps in
which both the input and output of wave fronts are identified
without difficulty in the lateral zones of the activation maps.
Although this measure does not avoid the influence of
breakthrough patterns or wave fronts that proceed in an
oblique way with respect to the epicardial surface, it does
minimize this source of error, which would imply overesti-
mation of the true conduction velocity. Although we have not
established the magnitude of this error, it appears to be
constant, because no significant differences were observed in
analysis of the reproducibility of the determinations. Con-
versely, the estimation of FRPVF based on the wave-front
dynamics implies an overestimation of this parameter in the
presence of an excitable gap. In this sense, the use of the
minimum values found contributes to reduction of the influ-
ence of this factor.
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Conclusions
(1) Flecainide and d,l-sotalol prolong WLVF, whereas verap-
amil shortens it. (2) An inverse relation exists between FrD
and WLVF, although this relation is more accentuated when
ventricular refractoriness is considered. (3) The drug-induced
modifications in activation frequency and WL are accompa-
nied by significant changes in reentrant wave-front size, with
increments induced by flecainide and d,l-sotalol and decre-
ments under the action of verapamil. (4) Despite the divergent
effects on activation frequency, WL, and reentrant circuit size
of verapamil with respect to flecainide and d,l-sotalol, all 3
antiarrhythmic drugs diminish the complexity of the activa-
tion patterns during VF.
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